Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Schönborn – page 41

1 165 clinical trials in Bad Schönborn, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Schönborn at a glance
1 165
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 165 trials in Bad Schönborn

Open in trial search

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Angina pectoris

Not yet recruiting

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glyceryl Trinitrate
  • Sponsor:G. Pohl-Boskamp GmbH & Co. KG

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Safety and Tolerability of Metformin in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Placebo‑Controlled Phase II Study

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Philipps-Universitaet Marburg

Influenza

Not yet recruiting

A Phase 3 Study of Efitazanamivir Alfa for Preventing Influenza in Adults and Adolescents at High Risk of Complications

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Cidara Therapeutics Inc.

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Hodgkin's disease

Not yet recruiting

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Schönborn

What the registry says about research in the country

01 Chronic Sinusitis Research

Innovative clinical trials exploring LYR-210 depot therapy for patients with chronic rhinosinusitis who haven't responded to conventional treatments. This research focuses on improving the three cardinal symptoms of CRS in patients without nasal polyps.

  • Chronic Rhinosinusitis Management
  • Non-Polyp CRS Treatment
  • Alternative Therapeutic Approaches

Research aims to provide new options for patients who have exhausted traditional medical management strategies.

02 House Dust Mite Allergy Studies

Comprehensive evaluation of subcutaneous immunotherapy for moderate to severe allergic rhinitis and rhinoconjunctivitis. The research examines a specialized treatment protocol using PURETHAL Mites Mixture for patients with or without concurrent asthma.

  • Allergic Rhinitis Treatment
  • Immunotherapy Efficacy
  • Combined Symptom Management

This study measures treatment effectiveness through the Total Combined Rhinitis Score over a one-year period.

03 Seasonal Allergy Research

Investigation of PQ Birch therapy for seasonal allergic conditions, specifically targeting birch pollen-induced rhinitis and rhinoconjunctivitis. The research evaluates both safety and efficacy parameters.

  • Seasonal Rhinitis Treatment
  • Birch Pollen Allergies
  • Therapeutic Innovation

The study focuses on developing targeted solutions for seasonal allergy sufferers during birch pollen season.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.